Table 5 Adverse events.

From: Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study

 

FTD/TPI (N = 70)

FTD/TPI plus ramucirumab (N = 36)

P value

Any grade

%

Grade ≥ 3

%

Any grade

%

Grade ≥ 3

%

Any grade

Grade ≥ 3

Any adverse events

70

100.0

45

64.3

36

100.0

26

72.2

1.000

0.514

Leucopenia

50

71.4

25

35.7

27

75.0

12

33.3

0.819

0.833

Neutropenia

51

72.9

33

47.1

30

83.3

22

61.1

0.334

0.219

Anemia

69

98.6

16

22.9

31

86.1

5

13.9

0.095

0.315

Thrombocytopenia

46

65.7

7

10.0

24

66.7

5

13.9

1.000

0.536

Fatigue

46

65.7

2

2.9

30

83.3

4

11.1

0.070

0.177

Decreased appetite

39

55.7

6

8.6

29

80.6

8

22.2

0.018

0.069

Nausea

34

48.6

2

2.9

25

69.4

1

2.8

0.063

1.000

Vomiting

16

22.9

1

1.4

9

25.0

0

0.0

0.813

1.000

Diarrhea

18

25.7

0

0.0

10

27.8

0

0.0

0.820

1.000

Stomatitis

7

10.0

0

0.0

7

19.4

0

0.0

0.227

1.000

Rash

5

7.1

1

1.4

6

16.7

0

0.0

0.178

1.000

Proteinuriaa

–

–

–

–

7

19.4

2

5.6

–

–

Febrile neutropenia

–

–

2

2.9

–

–

5

13.8

–

0.043

  1. FTD/TPI, trifluridine tipiracil
  2. aThe data on proteinuria in the FTD/TPI group was not evaluated.
Back to article page